Phase 2 Sickle cell disease trials recruiting now

All Sickle cell disease trials, every phase

Other phases for Sickle cell disease

Phase 2 Sickle cell disease trials

• A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
  NCT05953584 · Phase: Phase 2 · Ages: 12 Years to 16 Years · Sex: All (male and female) · 9 locations
• A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
  NCT05431088 · Phase: Phase 2, Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 80 locations
• A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
  NCT06546670 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 55 Years · Sex: All (male and female) · 10 locations
• A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
  NCT05736419 · Phase: Phase 2 · Ages: 2 Years to 50 Years · Sex: All (male and female) · 6 locations
• A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
  NCT06481306 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
  NCT06198712 · Phase: Phase 2 · Ages: 6 Months to 18 Years · Sex: All (male and female) · 18 locations
• A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
  NCT04201210 · Phase: Phase 2 · Ages: 2 Years to 35 Years · Sex: All (male and female) · 9 locations
• Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
  NCT05685368 · Phase: Phase 1, Phase 2 · Ages: 14 Years to 21 Years · Sex: All (male and female) · 1 location
• Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
  NCT06016634 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Allo HSCT for High Risk Hemoglobinopathies
  NCT06872333 · Phase: Phase 2 · Ages: Up to 55 Years · Sex: All (male and female) · 1 location
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
  NCT04099966 · Phase: Phase 2 · Ages: 1 Day to 30 Years · Sex: All (male and female) · 1 location
• Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
  NCT02447874 · Phase: Phase 1, Phase 2 · Ages: 7 Years to 21 Years · Sex: All (male and female) · 2 locations
• Cannabidiol in Sickle Cell Disease
  NCT06930703 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
  NCT05519111 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cognitive Remediation Intervention to Prepare for Transition of Care
  NCT05336201 · Phase: Phase 2 · Ages: 10 Years to 18 Years · Sex: All (male and female) · 1 location
• Early Screening and Treatment of Heart Complication in Sickle Cell Disease
  NCT07023666 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
  NCT07432867 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 35 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
  NCT07282210 · Phase: Phase 2 · Ages: 16 Years to 35 Years · Sex: All (male and female) · 4 locations
• Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
  NCT04819841 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 50 Years · Sex: All (male and female) · 6 locations
• Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
  NCT07616154 · Phase: Phase 2 · Ages: Up to 22 Years · Sex: All (male and female) · 1 location
• Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
  NCT06635902 · Phase: Phase 2 · Ages: 4 Years to 21 Years · Sex: All (male and female) · 1 location
• Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
  NCT06399107 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 90 Years · Sex: All (male and female) · 1 location
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
  NCT03587272 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · 7 locations
• Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
  NCT02675959 · Phase: Phase 2 · Ages: 6 Months to 21 Years · Sex: All (male and female) · 4 locations
• Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
  NCT03214354 · Phase: Phase 2 · Ages: 1 Year to 19 Years · Sex: All (male and female) · 1 location
• Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
  NCT06761560 · Phase: Phase 2, Phase 3 · Ages: 6 Months to 18 Years · Sex: All (male and female) · 1 location
• Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
  NCT07708714 · Phase: Phase 1, Phase 2 · Ages: 11 Years to 18 Years · Sex: All (male and female) · 1 location
• Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
  NCT07599176 · Phase: Phase 1, Phase 2 · Ages: 4 Years to 65 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
  NCT06578507 · Phase: Phase 2 · Ages: 9 Months to 11 Years · Sex: All (male and female) · 6 locations
• RH Genotype Matched RBC Transfusions
  NCT04156893 · Phase: Phase 1, Phase 2 · Ages: 6 Months and older · Sex: All (male and female) · 1 location
• Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
  NCT03128996 · Phase: Phase 1, Phase 2 · Ages: 1 Day to 21 Years · Sex: All (male and female) · 4 locations
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
  NCT01962415 · Phase: Phase 2 · Ages: 2 Months to 55 Years · Sex: All (male and female) · 2 locations
• Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
  NCT05583721 · Phase: Phase 2 · Ages: 18 Years to 21 Years · Sex: All (male and female) · 1 location
• Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
  NCT04008368 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 80 Years · Sex: All (male and female) · 1 location
• Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
  NCT07252050 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 45 Years · Sex: All (male and female) · 4 locations
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
  NCT07224360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
  NCT06699849 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 26 locations
• Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
  NCT06358638 · Phase: Phase 2 · Ages: 2 Years to 25 Years · Sex: All (male and female) · 1 location
• Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
  NCT03121001 · Phase: Phase 2 · Ages: 16 Years to 60 Years · Sex: All (male and female) · 1 location
• Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
  NCT07369024 · Phase: Phase 2 · Ages: 5 Years to 20 Years · Sex: All (male and female) · 1 location
• T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
  NCT03653338 · Phase: Phase 1, Phase 2 · Ages: 5 Years to 40 Years · Sex: All (male and female) · 1 location
• Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
  NCT07175051 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Tocilizumab for Acute Chest Syndrome
  NCT05640271 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 1 location
• Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
  NCT04774536 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 35 Years · Sex: All (male and female) · 2 locations
• Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
  NCT06260891 · Phase: Phase 2 · Ages: 15 Years to 40 Years · Sex: All (male and female) · 6 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.